The long-term haemodynamic effect of sustained-release trimazosin (mean daily dose 418 mg) at rest and during exercise has been examined in 14 male patients (age 30–61 y) with previously untreated mild or moderate essential hypertension. Cardiac output (dye dilution), heart rate and intra-arterial blood pressure were measured supine and sitting at rest, and during bicycle exercise.
After 11 months of trimazosin treatment the mean casual blood pressure was reduced from 165/106 mm Hg to 147/92 mm Hg. The intra-arterial systolic and diastolic pressure was reduced by 3–7% at rest and during 50, 100 and 150 W exercise. Total peripheral resistance was reduced by 8–14% and cardiac output was slightly higher (2–8%) in all situations.
Stroke volume and heart rate remained unchanged, as did body fluid volumes (isotope dilution) and body weight.
Side effects were minor and transient.
Thus, the haemodynamic responses to trimazosin are similar to but weaker than those of other alpha1-adrenoceptor blockers. The efficacy of the sustained-release formulation of trimazosin was low and daily doses above 600 mg are likely to be needed by many patients.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Reid JL, Meredith PA, Elliott HL (1983) Pharmacokinetics and pharmacodynamics of trimazosin in man. Am Heart J 106: 1222–1228
DeGuia D, Mendlowitz M, Russo C, Vlachakis ND, Simonne A (1973) The effect of trimazosin in essential hypertension. Curr Ther Res 15: 339–348
Constantine JW, Hess HJ (1981) The cardiovascular effects of trimazosin. Eur J Pharmacol 74: 227–238
Pool PE, Seagren SC, Salel AT (1983) Clinical haemodynamic profile of trimazosin in hypertension patients. Am Heart J 106: 1237–1242
Chrysant SG (1983) Autonomic, systemic and renal haemodynamic actions of trimazosin in hypertensive patients. Am Heart J 106: 1243–1250
Helgeland A (1983) Double-blind comparison of trimazosin and propranolol in essential hypertension. Am Heart J 106: 1253–1258
Sampieri L, Cuspidi C, Boselli L, Angioni L, Castiglioni G, Zanchetti Mancia G (1988) Effect on resting blood pressure and blood pressure homeostasis of short-term administration of the alpha1-adrenergic receptor antagonist, trimazosin, in hypertension. Cardiovasc Drugs Ther 1: 535–543
Flouvat B, Fodor F, Roux A, Bianchienne JR (1983) Pharmacokinetics of sustained-release trimazosin tablet formulation. Am Heart J 106: 1228–1234
Lund-Johansen P (1967) Haemodynamics in early essential hypertension. Acta Med Scand [Suppl 482] 1–101
Aronow WS, Tobis J, Huges D, Slegel J, Easthope J (1977) Comparison of trimazosin and methyldopa in hypertension. Clin Pharmacol Ther 22: 425–429
Taylor CR, Laeder JP, Singleton W, Munster EW, Falkner FC, O'Neil JA (1983) Profile of trimazosin: An effective and safe antihypertensive agent. Am Heart J 106: 1269–1281
Stanaszek WF, Kellerman D, Brogden RN, Romankiewicz JA (1983) Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs 25: 339–384
Lund-Johansen P (1974) Haemodynamic changes at rest and during exercise in long-term prazosin therapy of essential hypertension. In: DWK Cotton (ed) Prazosin — Evaluation of a new antihypertensive agent. Amsterdam, Excerpta Medica, pp 43–51
Lund-Johansen P, Omvik P, Haugland H (1986) Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise. Br J Clin Pharmacol 21: 45s-54s
About this article
Cite this article
Omvik, P., Lund-Johansen, P. Long-term haemodynamic effects of sustained-release trimazosin at rest and during exercise in essential hypertension. Eur J Clin Pharmacol 40, 131–134 (1991). https://doi.org/10.1007/BF00280066
- alpha1-adrenoceptor blocker
- extracellular fluid volume
- plasma volume
- side effects